OPKO HEALTH, INC. (OPK) Stock
OPK has an Alpha Score of 49 out of 100 (weak), computed on Nov 7, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 3 trades in OPK since 2017: 3 purchases and 0 sales, most recently Carlos Curbelo (purchase, Sep 26, 2017). 3 of the hedge funds AlphaScala tracks reported OPK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $2.13M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is OPK's Alpha Score?
How it works →Alpha Score of 49 reflects weak overall profile with strong momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 7, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded OPKO HEALTH, INC. (OPK)?
Most recent: Carlos Curbelo (purchase, Sep 26, 2017); records start Feb 7, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Carlos Curbelo R-FL · House | 2017-09-26 | purchase | $1k – $15k |
| Carlos Curbelo R-FL · House | 2017-03-02 | purchase | $1k – $15k |
| Carlos Curbelo R-FL · House | 2017-02-07 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all OPK political trades →Which hedge funds own OPK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.42M | $2.13M | -32% |
| Point72 Steve Cohen | 145K | $217.9K | +56% |
| Millennium Management Israel Englander | 72K | $108.5K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are OPKO HEALTH, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 5, 26 | Paganelli John A | Director | SELL | 4.4K | $8K |
| Nov 5, 26 | Paganelli John A | Director | SELL | 9.2K | $17K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are OPK's key statistics?
Key statistics as of Nov 7, 2026
How does OPK's valuation compare with the Healthcare sector?
| Metric | OPK | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -23.93% | 3.66% | 170 |
| Return on equity | -5.88% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
OPK price chart
Powered by TradingViewWhat does OPKO HEALTH, INC. do?
OpKO Health Inc. is a multinational biopharmaceutical and diagnostics company operating through two primary segments: Pharmaceuticals and Diagnostics. In the Pharmaceuticals segment, it develops and commercializes therapies such as Rayaldee, FDA-approved for treating secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency, and Somatrogon (hGH-CTP), approved in over 50 markets for growth hormone deficiency in children and adolescents. The company advances multispecific therapies targeting cancers and infectious diseases, partnering with leading pharmaceutical firms to deliver next-generation solutions for serious conditions across global markets. Its Diagnostics segment, primarily through BioReference Health, LLC, provides comprehensive clinical laboratory testing services, including the 4Kscore prostate cancer test, serving physicians, hospitals, clinics, and healthcare facilities nationwide with a network of labs. Founded in 1991 and headquartered in Miami, Florida, OpKO Health Inc. focuses on improving patient outcomes in healthcare and biopharmaceutical sectors.